AI Article Synopsis
- The study investigates the impact of the yellow fever vaccine (YFV) on patients with relapsing-remitting multiple sclerosis (RR-MS), who are generally advised against vaccination due to relapse risks.
- It utilized a non-interventional observational design, comparing relapse rates between 128 RR-MS patients who received YFV and those who did not.
- Findings indicate that there was no significant difference in annual relapse rates or time to first relapse between the two groups, suggesting YFV does not negatively affect RR-MS.
Article Abstract
Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses.
Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV.
Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS.
Results: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53-3.30, = 0.54).
Conclusion: These results suggest that YFV does not worsen the course of RR-MS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/13524585211006372 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!